DIN 02549131 — EBGLYSS 250 MG
EBGLYSS is a solution of Lebrikizumab marketed by ELI LILLY CANADA INC. The full Lebrikizumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02549131
- Brand name
- EBGLYSS
- Active ingredient
- Lebrikizumab
- Strength
- 250 MG
- Dosage form
- SOLUTION
- Route
- SUBCUTANEOUS
- Manufacturer
- ELI LILLY CANADA INC
- Health Canada status
- MARKETED
- Drug class
- Interleukin-13 (IL-13) inhibitor (monoclonal antibody)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Lebrikizumab products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02549123 | EBGLYSS | 250 MG | SOLUTION | ELI LILLY CANADA INC | MARKETED |